Technology for Detection of SARS-Cov-2 in HIV-Positive Cancer Patients

  • STATUS
    Recruiting
  • participants needed
    300
Send
Updated on 19 February 2024

Summary

The main purpose of this study is to try a new type of laboratory test for COVID-19 (also called SARS-CoV-2 or novel coronavirus).  COVID-19 is a new disease, so not enough is known about it yet.  This study hopes to collect more information about who is most as risk from this disease, how it affects different types of people, and how to test for it.
 
The current, FDA-authorized COVID-19 testing methods have some limitations, and it is not yet known how accurate (correct) they really are.  There are also not enough of those tests available yet, so not everyone who might have COVID-19 can get tested right away.  The researchers hope that the new lab test we are studying might turn out to be as good as or better than the current tests.  If so, this could help more people get tested for the disease sooner, which could give them a better chance of getting treated for it sooner, not getting as sick, and/or keep the disease from spreading to as many other people. 
 
This study is also looking at who might be most at risk for serious complications and/or death from COVID-19.  For example, it may be that people who already have other illnesses such as HIV (Human Immunodeficiency Virus), cancer, or other infections may be more likely to get very sick if they also get COVID-19.  To check for some such infections, we will take mucus samples from each person’s nose and mouth.  To compare how COVID-19 affects different groups of people, we will include in this study:
·      people who have HIV
·      people who have cancer
·      people who have both HIV and cancer
·      people who do not have HIV or cancer 
 
Another goal of this study is to figure out how a person’s immune system responds to COVID-19.  Some clues to changes in the immune system can be found in blood.  We will look for these clues in the blood sample we collect from you.
 

Description


FAQ


Details
Condition SARS-Cov-2,HIV,COVID19
Age 99years or below
Clinical Study IdentifierTX6479
Last Modified on19 February 2024

Eligibility

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.